| About us: |
 |
Exciting new advances in drug discovery, computational systems biology
and tissue engineering foreshadow a new era in regenerative medicine as
breakthrough technologies are made available to address a wide variety of
unsolved medical problems. The laboratory for converging technologies (LCT) is
focused on the synergistic integration of these important domains in biomedical
sciences and engineering for development of effective new strategies to repair,
replace, preserve or enhance tissue or organ function. Specific areas of interest
include 1) Regulation of inflammatory cell recruitment and tissue
neovascularization by phthalimide
neovascularization factors (PNFs) and phospholipid growth factors such
lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P); 2) Mechanistic
interrogation of drug therapies using network
analysis tools of cell signaling and tissue level remodeling; 3) Developing
enabling bioreactor
technologies to improve ex vivo tissue synthesis; 4) Developing biomimetic scaffold biomaterials
for bone and nerve tissue regeneration; and 5) Developing novel contact lenses delivering lacritin
for treatment of dry eye.
Click for lab news
|
Laboratory for Tissue Engineering